Grant: Master's Award: Canada Graduate Scholarships
University of Alberta
$17,500.00
Understanding the Immune Cell Phenotypes that Drive and Resolve Neuropathic Pain
FY 2023-24
Summary
Neuropathic pain (NP) which is often rated as ‘the worst pain imaginable’ impacts ~10% of the general population. However, the current therapies for NP management are only moderately effective. NP development is mediated by many different populations of immune cells. Importantly, these same cells also work to resolve NP suggesting that it is their cellular state that dictates which role they play.
Aim 1: Define NP-associated Immune Cell Phenotypes in Mice
I will use two mouse models of NP, one with resolving NP and the other with non-resolving NP. At various time points in the NP disease time course (e.g., when one model is recovering and the other is not), I will collect my tissue of interest and examine the cell type and gene expression profile of each immune cell present. By comparing the cell populations present in each model, I will identify molecular signatures associated with NP induction, resolution, and chronification.
Aim 2: Identify Pain Biomarkers and Therapeutic Targets for NP in Humans
I will examine blood samples from amputees with NP and those without to examine how NP alters the gene expression of blood-resident immune cells. I will then apply computational approaches to construct a network model that identifies the most meaningful cell populations to target with future therapeutics. This data may also identify biomarkers for NP that would give health care workers a quick and minimally invasive way (i.e., through a blood test) to gain a more complete understanding of a patient’s condition.
Aim 3: Draw Interspecies Comparisons
I will employ computational analysis on the data from Aim 1 and Aim 2 to compare NP-associated immune cell populations in mice and humans with NP. This will help to inform future clinical translation from mice to humans.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
506485
Name
Mohammed Lanah A
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Understanding the Immune Cell Phenotypes that Drive and Resolve Neuropathic Pain
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biomarkers; Clinical Translation; Immune Cell Heterogeneity; Immune Response; Molecular Targets For Novel Therapeutics; Nerve Injury; Neuropathic Pain; Pain Resolving Mechanisms; Pain Signatures; Single Cell/Nucleus Rna Sequencing
Abstract
Neuropathic pain (NP) which is often rated as ‘the worst pain imaginable’ impacts ~10% of the general population. However, the current therapies for NP management are only moderately effective. NP development is mediated by many different populations of immune cells. Importantly, these same cells also work to resolve NP suggesting that it is their cellular state that dictates which role they play.
Aim 1: Define NP-associated Immune Cell Phenotypes in Mice
I will use two mouse models of NP, one with resolving NP and the other with non-resolving NP. At various time points in the NP disease time course (e.g., when one model is recovering and the other is not), I will collect my tissue of interest and examine the cell type and gene expression profile of each immune cell present. By comparing the cell populations present in each model, I will identify molecular signatures associated with NP induction, resolution, and chronification.
Aim 2: Identify Pain Biomarkers and Therapeutic Targets for NP in Humans
I will examine blood samples from amputees with NP and those without to examine how NP alters the gene expression of blood-resident immune cells. I will then apply computational approaches to construct a network model that identifies the most meaningful cell populations to target with future therapeutics. This data may also identify biomarkers for NP that would give health care workers a quick and minimally invasive way (i.e., through a blood test) to gain a more complete understanding of a patient’s condition.
Aim 3: Draw Interspecies Comparisons
I will employ computational analysis on the data from Aim 1 and Aim 2 to compare NP-associated immune cell populations in mice and humans with NP. This will help to inform future clinical translation from mice to humans.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Mohammed, Lanah A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~